A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380 · FORAGER-2 Phase 3Recruiting
- Lead sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 450 (estimated)
- Start date
- 12 Dec 2025
- Primary completion
- Oct 2029 (estimated)
- Study completion
- 1 May 2033
- Last update posted
- 7 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 3
Interventions
- Vepugratinib Drug
- Placebo Other
- EV Drug
- Pembrolizumab Drug
Conditions and primary outcome
- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Neoplasm Metastasis
Primary outcome
Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab (From baseline up to 90 months); Safety Lead-in: Overall Response Rate (ORR) (From baseline up to 90 months); Progression-free Survival (PFS) (Baseline to Study Completion (estimated as 6 years))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07218380.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07218380 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.